Following white papers in September 2015 and February 2016, here Boehringer Ingelheim UK provides an update on its patient centricity initiative ahead of a new white paper later this year.

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...

Boehringer Ingelheim has signed a three-year agreement with the US startup for its Seqster operating system (SeqsterOS) and Digital Front Door platform, a portal that gathers together a patient's ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Patient centricity in artificial intelligence ... She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today.

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

These included reaction at the injection site, urinary tract infection, arthralgia, and pruritus, occurring at a rate of at least nine cases per 100 patient-years compared to the placebo arm.

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Nowadays, optimal cancer care encompasses the mind, body, spirit and emotions. Today's patient wants to take control and be an active participant in their cancer treatment. With this backdrop, ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...